INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to determine preliminary activity of the combination treatment with
nivolumab and entinostat in children and adolescents with high risk
refractory/relapsed/progressive tumors harboring a high mutational load, high PD-L1 mRNA
expression or focal MYC(N) amplification and explore activity in biomarker low tumors (low
mutational load, low PD-L1 mRNA expression and non-MYC(N) amplified).